Gaucher disease and the clinical experience with substrate reduction therapy

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 358, Issue 1433, 2003, Pages 961-966

  Zimran, Ari ^a   Elstein, Deborah ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Enzyme replacement therapy; Gaucher disease; Miglustat; Substrate reduction therapy

Indexed keywords

BIOCHEMISTRY;

EID: 0038777079     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2003.1272     Document Type: Conference Paper

References (26)

1. Abe, A., Wild, S. R., Lee, W. L. & Shayman, J. A. 2001 Agents for the treatment of glycosphingolipid storage disorders. Curr. Drug Metab. 2, 331-338.
2. Aerts, J. M., Hollak, C., Boot, R. & Groener, A. 2003 Biochemistry of glycosphingolipid storage disorders: implications for therapeutic intervention. Phil. Trans. R. Soc. Lond. B 358, 905-914. (DOI 10.1098/rstb.2003.1273.)
3. Barranger J. 2002 Improvements in enzyme replacement therapy. In National Organization for Rare Disorders (NORD) Conf. 11-13 October, Arlington, VA.
4. Barton, N. W. (and others) 1991 Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. New Engl. J. Med. 324, 1464-1470.
5. Beutler, E. & Grabowski, G. A. 2001 Gaucher disease. In The metabolic and molecular bases of inherited diseases, vol. III (ed. C. R. Scriver, D. Valle, A. Beudet & W. S. Sly), pp. 3635-3668. New York: McGraw-Hill.
6. Brady, R. O. 2003 Enzyme replacement therapy: conception, chaos and culmination. Phil. Trans. R. Soc. Lond. B 358, 915-919. (DOI 10.1098/rstb.2003.1269.)
7. Butters, T. D., Mellor, H. R., Narita, K., Dwek, R. A. & Platt, F. M. 2003 Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders. Phil. Trans. R. Soc. Lond. B 358, 927-945. (DOI 10.1098/rstb.2003.1278.)
8. Cox, T. (and 12 others) 2000 Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355, 1481-1485.
9. Dawson, A., Elias, D. J., Rubenson, D., Bartz, S. H., Garver, P. R., Kay, A. C., Bloor, C. M. & Beutler, E. 1996 Pulmonary hypertension developing after alglucerase therapy in two patients with type 1 Gaucher disease complicated by the hepatopulmonary syndrome. Ann. Intern. Med. 125, 901-904.
10. Dweck, A., Abrahamov, A., Hadas-Halpern, I., Bdolach-Avram, T., Zimran, A. & Elstein, D. 2002 Type I Gaucher disease in children with and without enzyme therapy. Pediatr. Hematol. Oncol. 19, 389-397.
11. Elstein, D., Klutstein, M. W., Lahad, A., Abrahamov, A., Hadas-Halpern, I. & Zimran, A. 1998 Echocardiographic assessment of pulmonary hypertension in Gaucher disease. Lancet 351, 1544-1546.
12. Elstein, D., Abrahamov, A., Hadas-Halpern, I. & Zimran, A. 2000 Withdrawal of enzyme replacement therapy in Gaucher disease. Br. J. Haematol. 110, 488-492.
13. Goitein, O., Elstein, D., Abrahamov, A., Hadas-Halpern, I., Melzer, E., Kerem, E. & Zimran, A. 2001 Lung involvement and enzyme replacement therapy in Gaucher disease. Q. J. Med. 94, 407-415.
14. Grabowski, G. A. & Horowitz, M. 1997 Gaucher's disease: molecular, genetic and enzymological aspects. Baillières Clin. Haematol. 10, 635-656.
15. Grabowski, G. A., Leslie, N. & Wenstrup, R. 1998 Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 12, 115-133.
16. Harats, D., Pauzner, R., Elstein, D., Many, A., Klutstein, M. W., Kramer, M. R., Farfel, Z. & Zimran, A. 1997 Pulmonary hypertension in two patients with type I Gaucher disease while in alglucerase therapy. Acta Hematol. 98, 47-50.
17. Heitner, R., Elstein, D., Aerts, J., van Weely, S. & Zimran, A. 2002 Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol. Dis. 28, 127-133.
18. Lee, R. E. 1982 The pathology of Gaucher disease. In Gaucher disease: a century of delineation and research (ed. R. J. Desnick, S. Gatt & G. A. Grabowski), pp. 177-217. New York: Alan R. Liss.
19. Moyses, C. 2003 Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease. Phil. Trans. R. Soc. Lond. B 358, 955-960. (DOI 10.1098/rstb.2003.1271.)
20. Platt, F. M., Neises, G. R., Dwek, R. A. & Butters, T. D. 1994 N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem. 269, 8362-8365.
21. Platt, F. M., Neises, G. R., Reinkensmeier, G., Townsend, M. J., Perry, V. H., Proia, R. L., Winchester, B., Dwek, R. A. & Butters, T. D. 1997 Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276, 428-431.
22. Platt, F. M., Jeyakumar, M., Andersson, U., Heare, T., Dwek, R. A. & Butters, T. D. 2003 Substrate reduction therapy in mouse models of the glycosphingolipidoses. Phil. Trans. R. Soc. Lond. B 358, 947-954. (DOI 10.1098/rstb.2003.1279.)
23. Radin, N. S. 1996 Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J. 13, 153-157.
24. Tierney, M. (and others) 1995 The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases. J. Acq. Immun. Def. Synd. Hum. Retrovir. 10, 549-553.
25. Weinreb, N. J. (and 10 others) 2002 Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med. 113, 112-119.
26. Wenstrup, R. J., Bailey, L., Grabowski, G. A. & Guo, S. 2001 Alendronate disodium improves bone mineral density in adults receiving enzyme replacement therapy (ERT) for Gaucher disease [abstract]. Am. J. Hum. Genet. 69(Suppl.), 674.